amphastar.com - AMPH Company profit before taxes, interest and amortization
Investments in complex biosimilar systems and innovative drug delivery are driving growth for Amphastar Pharmaceuticals (AMPH). The annual EBITDA figure on the GURU.Markets terminal chart confirms this potential, stabilizing at 206.49. Revenues are based on the sale of generics and emergency medical supplies. Stable demand for injectable drugs shields the company from economic cyclicality, ensuring the resilience of its financial results.
Amphastar Pharmaceuticals, Inc. (AMPH) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital|Short-Term Debt to Capital Amphastar Pharmaceuticals Inc|AMPH - Company Debts|Debt to Book Value Amphastar Pharmaceuticals|AMPH - Company Long-Term Debt|Current Liabilities Amphastar Pharmaceuticals|Intermediate Coverage Ratio amphastar.com
- earnings and market ratios statistics:
AMPH - Net Profit|Projected Future Earnings Amphastar Pharmaceuticals|AMPH - Price to Earnings Ratio|Market Cap to Projected Earnings amphastar.com|AMPH - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Amphastar Pharmaceuticals|AMPH - Operating profit EBITDA|Net earnings per share (EPS TTM) Amphastar Pharmaceuticals|AMPH - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months amphastar.com|AMPH - Net earnings per share growth this year|Expected earnings per share trend next year Amphastar Pharmaceuticals
Analysis of all company metrics:AMPH - Amphastar Corp
This indicator reflects the actual liquidity inflow from core operations, adjusted for the impact of taxes and debt obligations. By analyzing the consolidated EBITDA, an investor sees the actual speed of cash generation in a real-time assessment. The metric measures the efficiency of the operating cycle, excluding accounting distortions from depreciation. For Amphastar Pharmaceuticals (AMPH), this is critical during the transition from selling generics to implementing proprietary patented delivery systems. Steady growth in this line confirms the successful diversification of the business model.
Competitors of Amphastar Pharmaceuticals (AMPH)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA GLPG (Galapagos)|Operating profit EBITDA ANI Pharmaceuticals Inc ANIP|MNKD - Profit before payment of interest, taxes and amortization|Pacira Corp (PCRX) - Operating profit before deduction of amortization|ARS Pharmaceuticals (SPRY) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization TBPH (theravance.com)|AQST (Aquestive Therapeutics, Inc.) - Operating profit EBITDA|SCPH: Income before deduction of interest, taxes and amortization|Operating profit EBITDA TECX|Operating profit EBITDA Tonix Pharmaceuticals Holding (TNXP)|Profit before payment of interest, taxes and amortization China SXT Pharmaceuticals, Inc. SXTC|Operating income before deduction of amortization Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST: Operating profit before deduction of amortization|Invizyne Technologies - Company profit before taxes, interest and amortization|ORMP: Operating profit EBITDA|Entera Bio (ENTX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization MindWalk Holdings|ABVC: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CPIX (Cumberland Pharmaceuticals Inc.)|QNTM (Quantum BioPharma Ltd.) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization FibroGen Corp FGEN|TELO (Telomir Pharmaceuticals Corp) - Profit before deduction of interest, taxes, depreciation and amortization|Rani Therapeutics Inc - Operating profit EBITDA|Income before deduction of interest, taxes and amortization SNYR (Synergy CHC Corp)|RLYB: Operating profit EBITDA|Lexaria Bioscience Corp. (LEXX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Pulmatrix Corp|PTHL: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Aptorum Group Limited (APM)|Operating profit before deduction of amortization lyratherapeutics.com LYRA|Operating profit EBITDA IBO (Impact BioMedical)|Operating profit EBITDA TNF Pharmaceuticals Inc. TNFA|cbdMD Corp - Operating profit EBITDA|PainReform Corp (PRFX) - Operating profit before deduction of amortization|CYTO: Operating profit EBITDA|Profit before interest, taxes and amortization lipella.com (LIPO)|Operating profit before deduction of amortization OPTN|Operating profit EBITDA Pieris Pharmaceuticals Inc|Operating profit before deduction of amortization PROC (Procaps Group SA)|Company profit before taxes, interest and amortization PTPI|Operating profit EBITDA QLI (Qilian International)|Operating income before deduction of amortization acelyrin.com (SLRN)|TFF Pharmaceuticals, Inc. - Operating profit EBITDA
